• 3527 Citations
  • 29 h-Index
1988 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Antonietta Pia Falcone is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 19 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Thalidomide Medicine & Life Sciences
Melphalan Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Myelodysplastic Syndromes Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Prednisone Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1988 2019

  • 3527 Citations
  • 29 h-Index
  • 134 Article
  • 1 Letter
  • 1 Review article
20 Citations (Scopus)
Colorectal Neoplasms
Randomized Controlled Trials
GDC-0973
regorafenib
MPDL3280A
2 Citations (Scopus)

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study

Cremolini, C., Benelli, M., Fontana, E., Pagani, F., Rossini, D., Fucà, G., Busico, A., Conca, E., Di Donato, S., Loupakis, F., Schirripa, M., Lonardi, S., Borelli, B., Ongaro, E., Eason, K., Morano, F., Casagrande, M., Fassan, M., Sadanandam, A., De Braud, F. & 2 others, Falcone, A. & Pietrantonio, F., Mar 1 2019, In : ESMO Open. 4, 2, e000489.

Research output: Contribution to journalArticle

Open Access
Transverse Colon
irinotecan
Colonic Neoplasms
Microsatellite Repeats
Neoplasms
2 Citations (Scopus)

Circulating tumor DNA analysis in colorectal cancer: From dream to reality

Antoniotti, C., Pietrantonio, F., Corallo, S., De Braud, F., Falcone, A. & Cremolini, C., Jan 1 2019, In : JCO precision oncology. 3

Research output: Contribution to journalArticle

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable

Ongaro, E., Cremolini, C., Rossini, D., Corti, F., Pagani, F., Morelli, L., Urbani, L., Masi, G., Sposito, C., Filippi, B., Borelli, B., Zucchelli, G., Moretto, R., Boccaccino, A., Solaini, L., De Braud, F., Mazzaferro, V., Falcone, A., Cucchetti, A. & Pietrantonio, F., May 1 2019, In : ESMO Open. 4, 2, e000496.

Research output: Contribution to journalArticle

Open Access
Liver Neoplasms
Disease Progression
Colorectal Neoplasms
Neoplasm Metastasis
Liver

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F., Evangelista, A., Spada, S., Benevolo, G., Oddolo, D., Innao, V., Cangialosi, C., Bernardini, A., Musto, P., Amico, V., Fraticelli, V., Paris, L., Giuliani, N., Falcone, A. P., Zambello, R. & 7 others, De Paoli, L., Romano, A., Palumbo, A., Montefusco, V., Hajek, R., Boccadoro, M. & Bringhen, S., Jun 27 2019, In : Haematologica.

Research output: Contribution to journalArticle

Melphalan
Prednisone
Multiple Myeloma
Dexamethasone
Transplants